MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.

First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic pipeline.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

16/05/2019
MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of...
16/05/2019
MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of...
07/05/2019
MorphoSys AG Reports First Quarter 2019 Results
29/04/2019
MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3...
23/04/2019
MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with...
15/04/2019
MorphoSys Announces that its Licensee Janssen has Expanded Clinical...
10/04/2019
MorphoSys Nominates New Candidate for Supervisory Board
01/04/2019
Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and...
19/03/2019
MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study...
13/03/2019
MorphoSys Presents Results for Fiscal Year 2018

May 8, 2019
Conference call & Webcast
Q1 2019 Financial Results

Full details

 

 

 

 

Interview with
Simon Moroney, CEO